Search citation statements

Order By: Relevance
Select...
2
1
1
1
1
5
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

1
5
0
Order By: Relevance
“…As for lung function evaluated using PFT, we found that disease had stabilized after 12 months in all the subgroups of CTD-ILD treated with rituximab and that it remained stable until the end of follow-up. These results agree with those of a recent meta-analysis, in which rituximab was superior to other immunosuppressants for the stabilization or improvement of FVC and DLCO in patients with CTD-ILD [28,36]. In our study, HRCT also revealed radiological stabilization/improvement in almost two-thirds of patients; this was the same for both the UIP and NSIP patterns.…”
Section: Discussionsupporting
See 1 more Smart Citation
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 14 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…As for lung function evaluated using PFT, we found that disease had stabilized after 12 months in all the subgroups of CTD-ILD treated with rituximab and that it remained stable until the end of follow-up. These results agree with those of a recent meta-analysis, in which rituximab was superior to other immunosuppressants for the stabilization or improvement of FVC and DLCO in patients with CTD-ILD [28,36]. In our study, HRCT also revealed radiological stabilization/improvement in almost two-thirds of patients; this was the same for both the UIP and NSIP patterns.…”
Section: Discussionsupporting
“…However, as shown in a recent meta-analysis, rituximab is more effective for improving or stabilizing FVC and has a better safety profile in patients with CTD-ILD than standard treatment with immunosuppressants. However, given its high cost, rituximab is not considered a replacement for standard treatment as the first option; therefore, rituximab may be a better option for patients who do not respond to standard treatment or who experience adverse effects [36].…”
Section: Discussionmentioning
“…Several reviews with meta-analyses have been published recently regarding the efficacy of RTX in SSc (103)(104)(105)(106)(107)(108). These reviews have differences concerning study inclusion criteria and all suffer from the paucity of high-powered randomized studies.…”
Section: B Cells Can Interact With Other Cell Types and Promote Fibrosismentioning
“…In their meta-analysis, Xing et al selected 6 retrospective studies in which 242 patients with CTD-ILD had been included ( 17 ). Five out of 6 studies included patients with SSc-ILD and 1 included patients with RA-ILD.…”
Section: A Meta-analysis Of Patients With Ctd-ildmentioning